Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 23, 2015Journal of Clinical Oncology

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

View Full Paper
Ask AI
Bookmark
Share

Authors

NANabil AhmedHouston MethodistVBVita S. BrawleyHouston MethodistMHMeenakshi HegdeHouston Methodist

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ahmed et al. (2015) studied this question.

synapsesocial.com/papers/69d77489f44a16d01ef311a3https://doi.org/10.1200/jco.2014.58.0225
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High-dose therapy with autologous stem cell rescue for pediatric sarcomas2004 · 58 citations
  2. 2Cellular Immunotherapy for Soft Tissue Sarcomas2012 · 14 citations
  3. 3Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells2011 · 96 citations
  4. 4T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia2011 · 2,434 citations
  5. 5Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia2013 · 3,536 citations